Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet
British Journal of Cancer, Published online: 31 July 2023; doi:10.1038/s41416-023-02350-7Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet (Source: British Journal of Cancer)
Source: British Journal of Cancer - July 31, 2023 Category: Cancer & Oncology Authors: G. Sicard D. Protzenko S. Giacometti F. Barl ési J. Ciccolini R. Fanciullino Source Type: research
A case of CD74 ‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens
Patients with advanced NSCLC who achieve long-term survival should be assessed for the presence of a driver mutation via NGS testing. In patients showing good clinical response to PEM regimens, physicians should consider testing for ROS1/ALK rearrangement. AbstractPreviously, cytotoxic drugs were the only option for patients with non-small cell lung cancer (NSCLC) and the prognosis was poor. However, molecularly targeted therapies and immune checkpoint inhibitors represent a breakthrough in the treatment of advanced NSCLC and have improved survival rates. In addition, advances in next-generation sequencing (NGS) have revea...
Source: Thoracic Cancer - July 25, 2023 Category: Cancer & Oncology Authors: Satoshi Tanaka,
Nobuaki Yoshimura,
Ryo Asakawa,
Satoshi Tobita,
Moto Yaga,
Kiyonobu Ueno Tags: CASE REPORT Source Type: research
Cancers, Vol. 15, Pages 3718: A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show 18F-Fluorothymidine & ldquo;Flare & rdquo; on Positron Emission Tomography
Conclusions: The better radiological response and longer survival observed in patients with an 18F-FLT flare suggest the efficacy of the tracer as an indicator of the early therapeutic response to pemetrexed in NSCLC. (Source: Cancers)
Source: Cancers - July 22, 2023 Category: Cancer & Oncology Authors: Preetha Aravind Sanjay Popat Tara D. Barwick Neil Soneji Mark Lythgoe Katherina B. Sreter Jingky P. Lozano-Kuehne Mattias Bergqvist Neva Patel Eric O. Aboagye Laura M. Kenny Tags: Article Source Type: research
Using the neutrophil ‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed
ConclusionsThe NLR significantly predicted PFS and OS, whereas BMI predicted OS, in individuals who initially received Pemb-Plt-PEM for non-sq NSCLC. These factors might be prognosis predictors in non-sq NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - July 20, 2023 Category: Cancer & Oncology Authors: Hisao Imai,
Satoshi Wasamoto,
Takeshi Tsuda,
Yoshiaki Nagai,
Takayuki Kishikawa,
Ken Masubuchi,
Takashi Osaki,
Yosuke Miura,
Yukihiro Umeda,
Akihiro Ono,
Hiroyuki Minemura,
Yutaka Yamada,
Junichi Nakagawa,
Yuki Kozu,
Hirokazu Taniguchi,
Hir Tags: ORIGINAL ARTICLE Source Type: research
First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
Conclusion and relevance: In this model, T + D + CT was estimated to be less cost-effective than CT for patients with mNSCLC at a WTP threshold of $ 100,000 to $ 150,000 per QALY in the United States. When new combination therapies with remarkable effect become pivotal in the first-line treatment, the price reduction of durvalumab and tremelimumab may be necessary to achieve cost-effectiveness in future possible context. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - July 20, 2023 Category: Drugs & Pharmacology Source Type: research
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
AbstractCisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (tumor lysis syndrome). Preventative rasburicase is recommended in high-risk cas...
Source: International Journal of Clinical Oncology - July 16, 2023 Category: Cancer & Oncology Source Type: research
Effects of single nucleotide polymorphisms of the folylpolyglutamate synthase gene on pemetrexed administration-induced nephropathy
CONCLUSION: The number of FPGS SNPs may contribute to PEM-induced renal impairment. Detecting FPGS SNPs may help predict PEM-induced renal damage.PMID:37452621 | DOI:10.1111/bcp.15851 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuki Mitarai Ryosuke Tanino Kazuhisa Nakashima Takamasa Hotta Takeshi Isobe Yukari Tsubata Source Type: research
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Int J Clin Oncol. 2023 Jul 16. doi: 10.1007/s10147-023-02382-2. Online ahead of print.ABSTRACTCisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (...
Source: Clinical Breast Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuichi Ando Hiroyuki Nishiyama Hideki Shimodaira Nao Takano Emiko Sakaida Koji Matsumoto Koki Nakanishi Hideki Sakai Shokichi Tsukamoto Keigo Komine Yoshinari Yasuda Taigo Kato Yutaka Fujiwara Takafumi Koyama Hiroshi Kitamura Takashige Kuwabara Atsushi Yo Source Type: research
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Int J Clin Oncol. 2023 Jul 16. doi: 10.1007/s10147-023-02382-2. Online ahead of print.ABSTRACTCisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (...
Source: Clinical Genitourinary Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuichi Ando Hiroyuki Nishiyama Hideki Shimodaira Nao Takano Emiko Sakaida Koji Matsumoto Koki Nakanishi Hideki Sakai Shokichi Tsukamoto Keigo Komine Yoshinari Yasuda Taigo Kato Yutaka Fujiwara Takafumi Koyama Hiroshi Kitamura Takashige Kuwabara Atsushi Yo Source Type: research
Effects of single nucleotide polymorphisms of the folylpolyglutamate synthase gene on pemetrexed administration-induced nephropathy
CONCLUSION: The number of FPGS SNPs may contribute to PEM-induced renal impairment. Detecting FPGS SNPs may help predict PEM-induced renal damage.PMID:37452621 | DOI:10.1111/bcp.15851 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuki Mitarai Ryosuke Tanino Kazuhisa Nakashima Takamasa Hotta Takeshi Isobe Yukari Tsubata Source Type: research
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Int J Clin Oncol. 2023 Jul 16. doi: 10.1007/s10147-023-02382-2. Online ahead of print.ABSTRACTCisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (...
Source: Clinical Breast Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuichi Ando Hiroyuki Nishiyama Hideki Shimodaira Nao Takano Emiko Sakaida Koji Matsumoto Koki Nakanishi Hideki Sakai Shokichi Tsukamoto Keigo Komine Yoshinari Yasuda Taigo Kato Yutaka Fujiwara Takafumi Koyama Hiroshi Kitamura Takashige Kuwabara Atsushi Yo Source Type: research
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Int J Clin Oncol. 2023 Jul 16. doi: 10.1007/s10147-023-02382-2. Online ahead of print.ABSTRACTCisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (...
Source: Clinical Genitourinary Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuichi Ando Hiroyuki Nishiyama Hideki Shimodaira Nao Takano Emiko Sakaida Koji Matsumoto Koki Nakanishi Hideki Sakai Shokichi Tsukamoto Keigo Komine Yoshinari Yasuda Taigo Kato Yutaka Fujiwara Takafumi Koyama Hiroshi Kitamura Takashige Kuwabara Atsushi Yo Source Type: research
Corrigendum to “Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189” [Lung Cancer 155 (2021) 53–60]
The authors regret to inform that the content of Figure 4 is incorrect in the current version published online. We provide below the corrected version. We have verified that the rest of the manuscript content remains correct as is. (Source: Lung Cancer)
Source: Lung Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Edward B. Garon, Joachim Aerts, Jong Seok Kim, Catherine E. Muehlenbein, Patrick Peterson, Maria Teresa Rizzo, Shirish M. Gadgeel Tags: Corrigendum Source Type: research
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
CONCLUSION: This phase II trial is accruing patients at U.S. sites through the National Comprehensive Cancer Network (NCCN). The trial opened in August 2019 and accrual is expected to be completed in the Fall of 2024.PMID:37451930 | DOI:10.1016/j.cllc.2023.05.003 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - July 14, 2023 Category: Cancer & Oncology Authors: J Nicholas Bodor Jyoti D Patel Heather A Wakelee Benjamin P Levy Hossein Borghaei Bruna Pellini Michael R Costello Jonathan E Dowell Gene Finley Chao H Huang Joel W Neal Jorge J Nieva Sonam Puri Mark A Socinski Christian Thomas Eric A Ross Samuel Litwin M Source Type: research
